Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 2,171,585 shares, a drop of 24.8% from the April 15th total of 2,888,176 shares. Based on an average daily trading volume, of 3,600,517 shares, the short-interest ratio is currently 0.6 days. Approximately 1.4% of the company’s stock are short sold.
Institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. bought a new position in shares of Actinium Pharmaceuticals during the 1st quarter valued at $39,000. Renaissance Technologies LLC raised its holdings in shares of Actinium Pharmaceuticals by 69.9% during the 1st quarter. Renaissance Technologies LLC now owns 139,347 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 57,335 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Actinium Pharmaceuticals by 69.3% during the 1st quarter. Oppenheimer & Co. Inc. now owns 175,512 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 71,840 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Actinium Pharmaceuticals by 23.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 198,480 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares in the last quarter.
Shares of NYSEAMERICAN:ATNM opened at $0.29 on Thursday. Actinium Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $0.87.
A number of brokerages have issued reports on ATNM. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Monday, April 1st. Oppenheimer set a $5.00 target price on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, February 26th. Finally, Maxim Group reissued a “buy” rating and set a $3.00 target price on shares of Actinium Pharmaceuticals in a research note on Wednesday, March 20th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $3.50.
WARNING: This piece was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/23/actinium-pharmaceuticals-inc-atnm-short-interest-down-24-8-in-april.html.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Featured Story: The components of the Stochastic Momentum Index
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.